Which stocks might be disrupted next by Ozempic and other GLP-1 drugs

Shares of kidney dialysis providers fell sharply Wednesday after Novo Nordisk said a study showed its Ozempic drug could delay the onset of kidney disease in diabetes patients. This latest development reinforces the far-reaching implications GLP-1 medications could have on a wide variety of conditions, from liver disease to sleep apnea to heart disease. Initially developed as a treatment for diabetes, the drugs have shown benefits for other conditions, most notably weight loss .

Companies that fill injectable pens administered to patients could win as drugmakers scramble to meet growing demand. That could prove a major boon for companies such as Catalent and Thermo Fisher Scientific , both of which have reportedly tapped manufacturing agreements with Novo Nordisk, according to Reuters . Catalent shares have only risen about 3% year to date, while Thermo Fisher's slumped a little more than 10%.

مصر أحدث الأخبار, مصر عناوين

Similar News:يمكنك أيضًا قراءة قصص إخبارية مشابهة لهذه التي قمنا بجمعها من مصادر إخبارية أخرى.

Dialysis-company stocks slide after Ozempic trial's success in treating kidney diseaseDaVita’s stock was down 16%, while Baxter and Intuitive Surgical were down 9% and 6%
مصدر: MarketWatch - 🏆 3. / 97 اقرأ أكثر »

Ozempic for weight loss is disrupting companies’ business modelCompanies from Walmart Inc. to Conagra Brands Inc. are weighing how much to factor the diabetes drugs known as GLP-1s, increasingly being used for weight loss, into their strategies.
مصدر: mercnews - 🏆 88. / 68 اقرأ أكثر »